News | May 28, 2015

CVRx Barostim Therapy Clinical Trial Results Presented at ESC-Heart Failure Conference

One hundred forty-six patient trial finds Barostim device safe and effective at improving quality of life for heart failure patients

CVRx, Barostim therapy, heart failure, trial, ESC-Heart Failure, Muller-Ehmsen

May 28, 2015 — CVRx Inc. announced that positive results from the 'Barostim Therapy for Heart Failure' randomized, controlled clinical trial were presented at the ESC-Heart Failure 2015 Annual Conference in a late-breaking trial session. Results were presented by Prof. Jochen Müller-Ehmsen, M.D., Ph.D., from Asklepios Hospital Altona in Hamburg, Germany.

Safety and efficacy results with Barostim therapy comparing patients not previously treated with cardiac resynchronization therapy to patients who continued to suffer from advanced heart failure despite prior treatment with CRT were presented. At six months in the no-CRT group, Müller-Ehmsen reported that quality of life scores improved significantly, six-minute hall walk distance and left ventricular ejection fraction increased significantly, and heart failure hospitalization days were significantly reduced in Barostim therapy patients compared to controls.  

"Based on our own experience with Barostim therapy and the safety and efficacy data now published, we are very confident to offer this therapy to our heart failure patients who are still symptomatic despite receiving optimal heart failure therapy", Müller-Ehmsen said.

"Based on results of this trial we have had the good fortune of presenting the data at three late-breaking clinical trial sessions and generating two simultaneous publications over the last three months. This is unprecedented", said William Abraham, M.D., from The Ohio State University, who served on the trial's steering committee.

CVRx completed a 146-patient randomized, controlled clinical trial to determine the performance of Barostim therapy for patients suffering from chronic heart failure with advanced symptoms. Aggregate results were recently presented at the American College of Cardiology's (ACC) annual scientific session and simultaneously published in the Journal of the American College of Cardiology: Heart Failure. Barostim therapy was shown to be safe and significantly improved patient functional and exercise capability, as well as quality of life, when compared to optimal medical therapy. Barostim therapy also significantly reduced the plasma biomarkers of heart failure severity and the burden of heart failure hospitalizations in patients with heart failure.

Barostim neo is a second-generation device that uses CVRx-patented technology designed to trigger the body's own natural blood flow regulation system to treat patients suffering from chronic heart failure. The therapy is also a treatment option for patients with resistant hypertension. The system electrically activates the baroreflex, the body's natural mechanism to regulate cardiovascular function. By activating this afferent pathway, Barostim therapy reduces sympathetic activity and increases parasympathetic activity, ultimately restoring sympatho-vagal balance.

Key benefits include:

  • The Barostim neo can be turned on and off to demonstrate acute results;
  • It can be adjusted to meet each patient's individual therapy needs;
  • It is a reversible treatment, meaning the therapy can be turned off;
  • It provides 100 percent adherence to treatment by continuously activating the baroreflex;
  • It is compatible with and complementary to implantable cardiac rhythm management devices; and 
  • It is now magnetic resonance (MR)-conditional, or safe for use under specified condition in Europe.


For more information:

Related Content

Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Overlay Init